Last edited by Akinohn
Sunday, November 15, 2020 | History

1 edition of Dyslipidemia found in the catalog.

Dyslipidemia

Miroslava KarapetroviДЌ

Dyslipidemia

causes, diagnosis, and treatment

by Miroslava KarapetroviДЌ

  • 196 Want to read
  • 17 Currently reading

Published by Nova Science Publishers in Hauppauge, N.Y .
Written in English

    Subjects:
  • Dyslipidemias,
  • HDL Lipoproteins,
  • Physiology

  • Edition Notes

    Includes bibliographical references and index.

    Statementeditors, Miroslava Karapetrovič and Zlatko Ačimovič
    The Physical Object
    Paginationp. ;
    ID Numbers
    Open LibraryOL25061232M
    ISBN 109781621009177
    LC Control Number2011040279


Share this book
You might also like
Violin making.

Violin making.

Little Tom finds out about measuring

Little Tom finds out about measuring

asters of Ontario (Compositae: Astereae)

asters of Ontario (Compositae: Astereae)

Preposterous Papa

Preposterous Papa

Assimil Language Courses :Perfectionnement Anglais

Assimil Language Courses :Perfectionnement Anglais

Painters and sculptures of modern America

Painters and sculptures of modern America

NATO 1949 - 1999 OTAN

NATO 1949 - 1999 OTAN

psychological variables in human cancer

psychological variables in human cancer

Studies in the economics of farm management in Kerala (Alleppey and Quilon)

Studies in the economics of farm management in Kerala (Alleppey and Quilon)

Try to understand how the Alcoholics Anonymous program works

Try to understand how the Alcoholics Anonymous program works

Prez

Prez

National ceramics exhibition Calgary =

National ceramics exhibition Calgary =

Preparation for the CLEP, College-Level Examination Program

Preparation for the CLEP, College-Level Examination Program

Ancient Greece

Ancient Greece

Preterm labour and its consequences

Preterm labour and its consequences

Praises through sorrow and praises in faith

Praises through sorrow and praises in faith

Dyslipidemia by Miroslava KarapetroviДЌ Download PDF EPUB FB2

Reflecting current guidelines from the National Cholesterol Education Program, the book explains why, when, and how to treat dyslipidemia. Coverage includes dietary treatment, drug treatment, and recommendations for special populations such as patients with coronary heart disease, patients at high risk for coronary heart disease, patients with diabetes, women, older adults, young adults, and racial Format: Hardcover.

An ideal reference for practitioners and health care professionals who care for patients with abnormal lipids, Dyslipidemia: A Clinical Approach provides clinically relevant, user-friendly information on all aspects of this rapidly evolving field.

In addition to concise yet in-depth coverage of key topics, chapters include background information, evidence from the literature, and author commentary on conflicting or Price: $ Various experimental and clinical researches are going on related to the basic mechanisms and treatment of dyslipidemia.

This book will deliver an overview of dyslipidemia from distinct facets of physiopathology, ethnic differences, genetics and role in metabolic syndrome.1/5(1).

In this book, we assembled a group of world-renowned scholars in their field to address major areas in lipoprotein disorders Dyslipidemia is a major risk factor for cardiovascular disease, which is the leading cause of morbidity and mortality around the globe, particularly among aging populations.

Dyslipidemia Pocketcard Set 1st Edition by Borm Bruckmeier Publishing (Author) out of 5 stars 11 ratings. ISBN ISBN Why is ISBN important.

ISBN. This bar-code number lets you verify that you're getting exactly the right version or edition of a book. /5(10). The John Hopkins Textbook of Dyslipidemia by Peter O. Kwiterovich and Kwiterovich Jr. MD, Peter O. Statin-Ease® Muscle Pain Relief – Natural Supplement Combo, % Drug-Free, with CoQ10, Vitamin D, Magnesium, Carnitine, Citrulline & Other Key Ingredients, 30 stickpacks, Dyslipidemia book Orange 25% coupon applied.

Abnormalities in lipid metabolism are very commonly observed in obese patients. Approximately % of obese patients are dyslipidemic. The lipid abnormalities in obese patients include elevated serum triglyceride, VLDL, apolipoprotein B, and non-HDL Dyslipidemia book levels.

The increase in serum triglycerides is primarily due to increased hepatic production of VLDL but a decrease in the clearance Cited by: Pediatric primary or monogenic dyslipidemias are a heterogeneous group of disorders, characterized by severe elevation of cholesterol, triglycerides or rarely a combination of the two.

Monogenic hypercholesterolemias have elevated low-density lipoprotein-cholesterol (LDL-C) levels and very high risk of premature atherosclerotic Dyslipidemia book. They are caused by mutations in genes involved in the. Dyslipidemia Guidelines (,and ). These recommendations are intended to provide a reasonable and practical approach to care for specialists, physicians and allied health professionals.

They are subject to change as scientific knowledge and technology advance andFile Size: 2MB. Treatment Overview of Dyslipidemia Dyslipidemia is a powerful risk factor for coronary heart disease (CHD). Clinical trials conclusively have demonstrated that treatment of lipid disorders can reduce CHD morbidity and mortality.

Treatment of lipid disorders also helps prevent stroke and peripheral arterial disease. Basic Size: KB. Dyslipidemia is divided up into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition.

That Author: James Roland. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and by: 7.

Dyslipidemia is a major risk factor for atherosclerosis. Atherosclerosis is a disease process that affects the coronary, cerebral and peripheral arterial circulation. Coronary Heart Disease (CHD) The etiology of atherosclerosis is multifactorial but the cause-effect relationship between dyslipidemia and File Size: 2MB.

The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the. Dyslipidemia’s contribution to stroke varies across subtypes, and the association between dyslipidemia and ischemic stroke caused by atherosclerosis is the most well known.

Dyslipidemia is an important risk factor for atherosclerotic ischemic stroke, and multiple clinical trials have shown that aggressive statin therapy can lower the Cited by: 6. Diabetes is an especially significant secondary cause because patients tend to have an atherogenic combination of high TGs; high small, dense LDL fractions; and low HDL (diabetic dyslipidemia, hypertriglyceridemic hyperapo B).

Patients with type 2 diabetes are especially at risk. The combination may be a consequence of obesity, poor control of diabetes, or both, which may increase circulating.

Secondary forms of dyslipidemia also exist, and several drug classes may elevate cholesterol levels (eg, progestins, thiazide diuretics, glucocorticoids, β-blockers, isotretinoin, protease inhibitors, cyclosporine, mirtazapine, and sirolimus).

The primary defect in familial hypercholesterolemia is inability to bind LDL to the LDL receptor (LDL-R). The initial step is to decide which particular lipid/lipoprotein abnormalities need to be evaluated and whether they need treatment. These disorders can be divided into elevations of plasma LDL, elevations of plasma triglycerides, and decreases in plasma HDL.

Frequently a patient can have multiple lipid/lipoprotein abnormalities. The next step is to rule out secondary causes that could account Cited by: 1.

Dyslipidemia-related complications (e.g., heart disease, stroke) year atherosclerotic cardiovascular disease (ASCVD) risk assessment (only if primary prevention) Current medications that may contribute to dyslipidemia.

LDL-C reduction based on statin benefit group, if applicable to patient (see Table ). The Primary Hyperlipidemia Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — all in one place for your convenience.

Mark Houston MD, MS, MSc, in Integrative Medicine (Fourth Edition), Nutrition. Nutrition is an important treatment for dyslipidemia, CHD risk factors, and the prevention and treatment of us epidemiological studies and prospective clinical trials, including the Framingham Heart Study, 54,55 Seven Countries Study, 56,57 Pritikin diet studies, Ornish Lifestyle Heart.

Chronic kidney disease (CKD) is associated with a dyslipidemia comprising high triglycerides, low HDL-cholesterol and altered lipoprotein composition. Cardiovascular diseases are the leading cause of mortality in CKD, especially in end stage renal disease patients. Thus, therapies to reduce cardiovascular risk are urgently needed in CKD.

Robust clinical trial evidence has found that use of Cited by: 9. The first comprehensive text on dyslipidemia from a major academic institution, this book covers all aspects of dyslipidemia as it relates to human disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and pancreatitis.

The material is presented in a. The Novel Agents Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — all in.

Dyslipidemia is a major pathogenic factor of atherosclerosis, and one of the independent risk factors for cardiovascular disease such as coronary heart disease and stroke [1,5].

Increasing the awareness and management of patients with dyslipidemia has a positive impact on cardiovascular disease by:   A dyslipidemia diet is a diet aimed at dealing with dyslipidemia before it does too much damage to your body.

But what is dyslipidemia?The medical dyslipidemia definition states that it is an excessive amount of lipids in the blood, which includes having high bad cholesterol (also known as low density lipoprotein; LDL) and triglycerides (a type of fat).

Home > Books > Dyslipidemia. Downloaded: Abstract. The clinical presentations of atherosclerotic disease are the result of a constellation of diverse metabolic and immunologic mechanisms ultimately set into motion by the formation of fatty acid streaks and the accompanying inflammatory cell activation, endothelial damage, smooth muscle Cited by: 1.

Management of Dyslipidemia in Adults in Red book. Montvale, N.J.: Medical Economics Data, Cost to the patient will be higher, depending on prescription filling fee. Cited by: Pathophysiology of Dyslipidemia in the Metabolic Syndrome Article Literature Review (PDF Available) in Postgraduate medical journal 81() July with 3, Reads.

A person with dyslipidemia has abnormal levels of lipids—such as cholesterol and triglycerides— in their blood. Cholesterol comes in many forms: HDL is known as “good” cholesterol. Women with diabetes should keep their HDL levels above 50 mg/dl; above 40 mg/dl for men. The third edition of Hypertension: A Companion to Braunwald's Heart Disease, by Drs.

George L. Bakris and Matthew Sorrentino, focuses on every aspect of managing and treating patients who suffer from hypertensive disorders. Designed for cardiologists, endocrinologists and nephrologists alike, this expansive, in-depth review boasts expert guidance from contributors worldwide, keeping you.

Multiple studies have shown a strong correlation between low-density lipoprotein cholesterol (LDL-C) concentration and development as well as progression of atherosclerosis and cardiovascular disorders.

Thus, the decrease of the LDL-C burden through lifestyle modification and/or pharmacological interventions unanimously demonstrated a decrease in cardiovascular events and mortality.

To date Author: Olta Tafaj Reddy. The first comprehensive text on dyslipidemia from a major academic institution, this book covers all aspects of dyslipidemia as it relates to human disease, including coronary artery disease, cerebrovascular disease, peripheral vascular disease, and pancreatitis. Dyslipidemia due to secondary causes is common.

In a cohort of new patients referred to a lipid clinic at an academic medical center in the United States, 28 percent had one or more potential causes of secondary dyslipidemia.

The most common conditions that were felt to be contributing to dyslipidemia were excessive alcohol intake ( The Pharmacotherapy Self-Assessment Program provides three releases per year (January, May, and September).

The content of these releases will assist the pharmacist in analyzing the latest evidence-based information and in translating that information into patient care to improve outcomes.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia.

Likewise, increased levels of O-GlcNAc transferase (OGT Specialty: Cardiology. The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the forefront of the diagnosis and management of dyslipidemia.

Case Studies in the Management of Dyslipidemia by Shana Lettieri, PharmD, and Tricia M. Russell, PharmD, BCPS, CDE pon successful completion of this continuing education activity, the pharmacist should be able to: 1.

Determine a patient’s risk for coro-nary heart disease and treatment goals. Recommend appropriate pharmacotherapyFile Size: 2MB. Various experimental and clinical researches are going on related to the basic mechanisms and treatment of dyslipidemia.

This book will deliver an overview of dyslipidemia from distinct facets of prevention, health hazards and treatment.

Product Identifiers. Publisher. Dyslipidemia by Ragavendra R Baliga, MD, MBA, Frcp, Facc starting at $ Dyslipidemia has 1 available editions to buy at Half Price Books Marketplace.

Since dyslipidemia is a major factor in the atheroscerlotic process, the advent of highly effective cholesterol-lowering medication has become a major tool in preventing atherosclerosis and subsequent heart attacks and strokes.

Pharmacists play a key role in monitoring and managing the therapeutic regimens of patients with dyslipidemia. + +.Niacin or nicotinic acid has been used for the management of dyslipidemia for over 50 years, and it is the first medication that has been shown to reduce both coronary disease events and mortality.

It is unique among the various lipid therapies in that it can not only reduce all of atherogenic lipid fractions (total cholesterol, low-density lipoprotein, very low-density lipoprotein, non-HDL Cited by: 1.Print book: EnglishView all editions and formats Summary: As part of the Oxford American Cardiology Library, this practical handbook is designed to serve as a concise yet authoritative resource on diagnosing and treating dyslipidemia.